Arthritis Clinical Trials

This randomized, placebo-controlled, double-blind study will compare the safety and efficacy of tapering methotrexate (MTX) versus maintaining MTX dosage in patients with severe active rheumatoid arthritis and an inadequate response to disease-modifying antirheumatic drugs (DMARDs) initiated on treatment with RoActemra/Actemra. Patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks and MTX orally weekly throughout the study. At Week 24, patients achieving a good/moderate EULAR response will be randomized to Group A receiving tapering doses of MTX or Group B maintaining their dose of MTX. Anticipated time on study treatment is 56 weeks.